do not combine dpp-4 inhibitors with glp-1 receptor agonists guidance The effect of inhibitors, and SGLT-2 on cardiorenal outcomes: a network meta-analysis of 23 CVOTs | Cardiovascular Diabetology The pharmacology of DPP-4 inhibitors

Although GLP-1RAs can reduce body weight by 15%25% in controlled settings, real-world adherence is limited, and nearly 70% of patients experience weight regain after discontinuation, raising the risk of long-term pharmacological dependence ( Looking ahead, the future of GLP-1based therapy will depend on addressing safety concerns, improving long-term adherence, and expanding clinical indications

At present, several GLP-1 analogs have joined the class, such as exenatide, liraglutide, dulaglutide, semaglutide and tirzepatide [1]

The FDA on Friday accepted Novo Nordisk s New Drug Application for an oral formulation of its widely popular obesity drug Wegovy for chronic weight management, bringing the Danish drugmaker one step closer to winning the first regulatory approval for a GLP-1 pill specifically for weight-loss

Our firm fights to obtain full compensation, not just quick settlements

Shima Hadidchi, MD , is committed to providing the latest, evidence-based treatments for weight management